First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (GDFATHER)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04725474 |
Recruitment Status :
Recruiting
First Posted : January 26, 2021
Last Update Posted : January 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor, Adult | Biological: CTL-002 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 155 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients will be assigned to a dose level of CTL-002 at the time of their enrollment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, First-in-human (FIH), Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors, That Relapsed Post or Were Refractory to a Prior Anti-PD-1/PD-L1 Therapy and Have Exhausted All Available Approved Standard Treatments or Are Not Eligible for Them Anymore (the "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Effector Cell Relocation). |
Actual Study Start Date : | December 9, 2020 |
Estimated Primary Completion Date : | May 31, 2023 |
Estimated Study Completion Date : | May 31, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A: CTL-002 Monotherapy + Checkpoint Inhibitor Combination Dose Escalation
Up to five dose levels with CTL-002 administered as IV monotherapy and in combination with an checkpoint inhibitor
|
Biological: CTL-002
monoclonal antibody |
Experimental: Part B: CTL-002 Monotherapy + Checkpoint Inhibitor combination
Up to 2 dose levels with CTL-002 in Part B (expansion)
|
Biological: CTL-002
monoclonal antibody |
- Adverse Events (Parts A & B) [ Time Frame: min. 2 months ]Incidence of treatment emergent adverse events in monotherapy and/or combination therapy
- Determination of DLT and MTD (Part A) [ Time Frame: 28 days ]Assessment of toxicities in monotherapy and/or combination therapy per dose level
- Evaluation of clinical efficacy according RECIST (Part B) [ Time Frame: min. 6 weeks ]RECIST is measured every 6-8 weeks treatment
- Cmax following the first dose of CTL-002 (Part A & B) [ Time Frame: 1 day ]PK parameter from serum CTL-002 levels
- AUC following the first dose of CTL-002 (Part A & B) [ Time Frame: 14 days ]PK parameter from serum CTL-002 levels
- Half-life of CTL-002 (Part A & B) [ Time Frame: min. 6 weeks ]PK parameter from serum CTL-002 levels
- Evaluation of treatment-emergent cytokine/chemokine concentrations (including TNF-a, IFN-g, IL-2, CXCL-9 and CXCL-10) (Part A & B) [ Time Frame: min. 6 weeks ]Measurement of concentration in peripheral blood
- Evaluation of clinical efficacy according RECIST (Part A) [ Time Frame: min. 6 weeks ]RECIST is measured every 6-8 weeks during treatment
- Evaluation of appetite [ Time Frame: min. 6 weeks ]Assessment of appetite via quality of life questionnaire
- Assessment of Body-Mass-Index (BMI) (kg/m2) [ Time Frame: min. 6 weeks ]Calculation of BMI in kg/m2 by combining measurement of body weight in kg and body height in cm
- Assessment of lumbar vertebra skeletal muscle index (L3SMI) (cm2/m2) [ Time Frame: min. 6 weeks ]Combining measurement of L3 vertebra skeletal muscle mass via computed tomography (CT) in cm2 and patient height (squared) in m2

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
- Male or female aged ≥ 18 years.
- Relapsed/refractory patients with histologically or cytologically confirmed diagnosis of advanced-stage or recurrent cancer
- Progressed on/relapsed after at least one prior anti-PD-1/PD-L1 treatment
- Biopsy-accessible tumor lesions and willing to undergo triple sequential tumor biopsy (Part A).
- At least 1 radiologically measurable lesion per RECIST V1.1/imRECIST (Part B).
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Life expectancy > 3 months as assessed by the Investigator.
- Adequate organ function (bone marrow, hepatic, renal function and coagulation).
Main Exclusion Criteria:
- Pregnant or breastfeeding.
- Any tumor-directed therapy within 21 days before study treatment.
- Treatment with investigational agent within 21 days before study treatment.
- Radiotherapy within 14 days before study treatment.
- Pre-existing arrhythmia, uncontrolled angina pectoris, uncontrolled heart failure (NYHA II-IV), any myocardial infarction/coronary event, CNS-ischemic event and any thromboembolic event at any time < 6 months prior to Screening.
- Left ventricular ejection fraction (LVEF) < 50% measured by echocardiogram or MUGA.
- QTcF > 450 ms for men or > 470 ms for women.
- Any active autoimmune requiring systemic immunosuppressive treatments. .
- Any history of non-infectious pneumonitis < 6 months prior to Screening.
- Any active inflammatory bowel disease such as Crohn's disease or ulcerative colitis which are generally excluded or active autoimmunthyroiditis present < 6 months prior to Screening.
- History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (< 6 months prior to Screening).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04725474
Contact: Eugen Leo, MD, PhD, MBA / CMO | +49 89 200066440 | eugen.leo@catalym.com | |
Contact: Petra Fettes, PhD | +49 89 200066440 | petra.fettes@catalym.com |
Germany | |
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik | Not yet recruiting |
Essen, Germany, 45147 | |
Universitätsklinikum Würzburg, Comprehensive Cancer Center | Not yet recruiting |
Würzburg, Germany, 97078 | |
Spain | |
Hospital Universitari Vall d'Hebron, Institute of Oncology | Not yet recruiting |
Barcelona, Spain, 08035 | |
START Madrid, Hospital Universitario HM Sanchinarro | Recruiting |
Madrid, Spain, 28050 | |
Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos | Recruiting |
Pamplona, Spain, 31008 | |
Switzerland | |
University Hospital Zurich, Department of Dermatology | Not yet recruiting |
Zurich, Switzerland, 9091 |
Study Director: | Eugen Leo, MD, PhD, MBA | CatylYm GmbH |
Responsible Party: | CatalYm GmbH |
ClinicalTrials.gov Identifier: | NCT04725474 |
Other Study ID Numbers: |
CTL-002-001 |
First Posted: | January 26, 2021 Key Record Dates |
Last Update Posted: | January 26, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
CTL-002 GDF-15 |